Роль асимметричного диметиларгинина в патогенезе сосудистых осложнений сахарного диабета
https://doi.org/10.24884/1682-6655-2012-11-4-91-94
Аннотация
Сахарный диабет является одним из наиболее распространенных хронических заболеваний и представляет собой серьезную проблему здравоохранения, в первую очередь, в силу развития осложнений. Развитие эндотелиальной дисфункции является одним из наиболее ранних событий в патогенезе сосудистых осложнений сахарного диабета. Асимметричный диметиларгинин (АДМА), являющийся хорошо известным маркером сердечно-сосудистого риска, может играть роль и при сахарном диабете. Результаты исследований, проведенных в последние годы, остаются противоречивыми. В данном кратком обзоре сделана попытка оценить взаимосвязь уровня АДМА с развитием эндотелиальной дисфункции и сосудистых осложнений при сахарном диабете.
Об авторах
Е. Н. Кравчук
Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова
Россия
Россия
М. М. Галагудза
Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова; Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова
Россия
Россия
А. А. Карпов
Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова
Россия
Россия
А. В. Федоров
Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова
Россия
Россия
Р. Н. Родионов
Технологический Университет Дрездена
Россия
Россия
Список литературы
1. Родионов, Р. Н. Асимметричный диметиларгинин и его роль в этиологии и патогенезе сердечно-сосудистых заболеваний / Р. Н. Родионов [и др.] // Артериальная гипертензия. - 2008. - Т. 14. - № 4. - С. 306-314.
2. Рябов, С. И. Внутренние болезни / С. И. Рябов, В. А. Алмазов, Е. В. Шляхто. - СПб.:Спецлит., 2001. - 861 с.
3. Abbasi, F. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus / F. Abbasi [et al] // Am. J. Cardiol. - 2001. - Vol. 88. - № 10. - P. 1201-1203.
4. Abhary, S. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines / S. Abhary [et al] // Diabetes Care. - 2009. - Vol. 32. - № 11. - P. 2084-2086.
5. Altinova, A. E. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations / A. E. Altinova [et al] // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92. - № 5. - P. 1881-1885.
6. Anderssohn, M. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: An intriguing interaction with diabetes mellitus / M. Anderssohn [et al.] // Diab. Vasc. Dis. Res. - 2010. - Vol. 7. - № 2. - P. 105-118.
7. Anthony, S. Endogenous production of nitric oxide synthase inhibitors / S. Anthony [et al.] // Vasc. Med. - 2005. - Vol. 10. - Suppl. 1. - P. S3-S9.
8. Boger, R. H. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease / R. H. Boger [et al.] // Circulation. - 1997. - Vol. 95. - № 8. - P. 2068-2074.
9. Boger, R. H. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: its role in hypercholesterolemia / R. H. Boger [et al.] // Circulation. - 1998. - Vol. 98. - № 18. - P 1842-1847.
10. Boger, R. H. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia / R. H. Boger [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - № 6. - P. 1557-1564.
11. Boger, R. H. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community / R. H. Boger [et al.] // Circulation. - 2009. - Vol. 119. - № 12. - P. 1592-1600.
12. Cavusoglu, E. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography / E. Cavusoglu [et al.] // Atherosclerosis. - 2010. - Vol. 210. - № 1. - P. 226-231.
13. Cooke, J. P. Asymmetrical dimethylarginine: the Uber marker? / J. P. Cooke // Circulation. - 2004. - Vol. 109. - № 15. - P. 1813-1818.
14. Didion, S. P. Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes / S. P. Didion [et al.] // Stroke. - 2005. - Vol. 36. - № 2. - P. 342-347.
15. Eid, H. M. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin / H. M. Eid [et al.] // Atherosclerosis. - 2003. - Vol. 166. - № 2. - P. 279-284.
16. Ellger, B. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity / B. Ellger [et al.] // Endocrinology. - 2008. - Vol. 149. - № 6. - P. 3148-3157.
17. Gunnett, C. A. Gene-targeted mice reveal a critical role for inducible nitric oxide synthase in vascular dysfunction during diabetes / C. A. Gunnett [et al.] // Stroke. - 2003. - Vol. 34. - № 12. - P. 2970-2974.
18. Hanai, K. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes / K. Hanai [et al.] // Nephrol. Dial. Transplant. - 2009. - Vol. 24. - № 6. - P. 1884-1888.
19. Heilman, K. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes / K. Heilman [et al.] // Scand. J. Clin. Lab. Invest. - 2009. - Vol. 69. - № 1. - P. 85-91.
20. Howard, B. V. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology / B. V. Howard [et al.] // Circulation. - 2002. - Vol. 105. - № 18. - P. e132-e137.
21. Jehlicka, P. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1 / P. Jehlicka [et al.] // Physiol. Res. - 2009. - Vol. 58. - № 2. - P. 179-184.
22. Kanazawa, I. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus /I. Kanazawa [et al.] // Clin. Endocrinol. - 2011. - Vol. 74. - № 4. - P. 467-472.
23. Konukoglu, D. The relationship between plasma asymmetrical dimethyl-l-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance / D. Konukoglu [et al.] // Metabolism. - 2008. - Vol. 57. - № 1. - P 110-115.
24. Lee, I. S. Specific expression of alanine-glyoxylate aminotransferase 2 in the epithelial cells of Henle's loop /1. S. Lee [et al.] // Nephron. - 1999. - Vol. 83. - № 2. - P 184-185.
25. Leiper, J. Disruption of methylarginine metabolism impairs vascular homeostasis / J. Leiper [et al.] // Nat. Med. - 2007. - Vol. 13. - № 2. - P. 198-203.
26. Lin, K. Y. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase / K. Y. Lin [et al.] // Circulation. - 2002. - Vol. 106. - № 8. - P. 987-992.
27. Marcovecchio, M. L. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes / M. L. Marcovecchio [et al.] // Clin. Sci. - 2008. - Vol. 115. - № 12. - P. 361-369.
28. Mittermayer, F. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus / F. Mittermayer [et al.] // Wien. Klin. Wochenschr. - 2005. - Vol. 117. - № 23-24. - P. 816-820.
29. Miyazaki, H. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis / H. Miyazaki [et al.] // Circulation. - 1999. - Vol. 99. - № 9. - P 1141-1146.
30. Nijveldt, R. J. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality / R. J. Nijveldt [et al.] // Clin. Nutr. - 2003. - Vol. 22. - № 1. - P. 23-30.
31. Ogawa, T. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney / T. Ogawa [et al.] // J. Biol. Chem. - 1989. - Vol. 264. - № 17. - P. 10205-10209.
32. Ogawa, T. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2 / T. Ogawa [et al.] // J. Biol. Chem. -1990. - Vol. 265. - № 34. - P 20938-20945.
33. Paiva, H. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerularfiltration rate but not with risk factors of vasculopathy / H. Paiva [et al.] //Metabolism. - 2003. - Vol. 52. - № 3. - P. 303-307.
34. Pettersson, A. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia / A. Pettersson [et al.] // Acta Obstet. Gynecol. Scand. - 1998. - Vol. 77. - № 8. - P. 808-813.
35. Siroen, M. P. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? / M. P. Siroen [et al.] // Crit. Care Med. - 2005. - Vol. 33. - № 3. - P. 504-510.
36. Stojanovic, I. The importance of l-arginine metabolism modulation in diabetic patients with distal symmetric polyneuropathy / I. Stojanovic [et al.] // J. Neurol. Sci. - 2012. - DOI: 10.1016/j.jns.2012.09.026.
37. Sugai, M. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients / M. Sugai [et al.] // Endocr. J. - 2007. - Vol. 54. - № 2. - P. 303-309.
38. Surdacki, A. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension / A. Surdacki [et al.] // J. Cardiovasc. Pharmacol. - 1999. - Vol. 33. - № 4. - P. 652-658.
39. Sydow, K. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity / K. Sydow [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2008. - Vol. 28. - № 4. - P. 692-697.
40. Tarnow, L. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes / L. Tarnow [et al.] // Diabetes Care. - 2004. - Vol. 27. - № 3. - P 765-769.
41. Usui, M. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure / M. Usui [et al.] // Life Sci. - 1998. - Vol. 62. - № 26. - P 2425-2430.
42. Valkonen, V. P. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine / V. P. Valkonen [et al.] // Lancet. - 2001. - Vol. 358. - P 2127-2128.
43. Wild, S. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 / S. Wild [et al.] // Diabetes Care. - 2004. - Vol. 27. - P. 1047-1053.
44. Woodman, R. J. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy / R. J. Woodman [et al.] // Drugs. - 2005. - Vol. 65. - P. 31-74.
45. Xiong, Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes / Y. Xiong [et al.] // Life Sci. - 2005. - Vol. 77. - P. 149-159.
46. Yoo, J. H. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke / J. H. Yoo, S. C. Lee // Atherosclerosis. - 2001. - Vol. 158. - № 2. - P. 425-430.
47. Zoccali, C. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study / C. Zoccali [et al.] // Lancet. - 2001. - Vol. 358. - P. 2113-2117.
Рецензия
Для цитирования:
Кравчук Е.Н., Галагудза М.М., Карпов А.А., Федоров А.В., Родионов Р.Н. Роль асимметричного диметиларгинина в патогенезе сосудистых осложнений сахарного диабета. Регионарное кровообращение и микроциркуляция. 2012;11(4):91-94. https://doi.org/10.24884/1682-6655-2012-11-4-91-94
For citation:
Kravchuk E.N., Galagudza M.M., Karpov A.A., Fedorov A.V., Rodionov R.N. The role of asymmetric dimethylarginine in the pathogenesis of vascular disease in diabetes mellitus. Regional blood circulation and microcirculation. 2012;11(4):91-94. (In Russ.) https://doi.org/10.24884/1682-6655-2012-11-4-91-94
Просмотров:
437
Послать статью по эл. почте 
